CD8A and neoplasm: Both CD4+ and CD8+ cells were able to efficiently kill KMS11-luc tumor cells in a BsAb dose-dependent manner, although we observed a slight shift in the half-maximal effective concentration (EC50) values for these two cell types (Figure 1C), suggesting that CD8+ T cells may more efficiently kill tumor cells in response to suboptimal BsAb doses, in line with their prototypical effector roles.